Susan Galbraith on AstraZeneca’s Grand Presence at ASH25
Susan Galbraith, Executive Vice President Oncology Haematology R&D at AstraZeneca, shared on LinkedIn:
”It’s been a great few days at ASH25, and I am very proud that AstraZeneca had its largest presence to date, reflecting our haematology research strategy in action.
We shared scientific updates on our T‑cell engager research targeting CD19 and on cell therapy approaches, including our investigational BCMAxCD19 CAR‑T programme.
These efforts are focused on better understanding immune‑based approaches in blood cancers and coming away from ASH I’m encouraged by the science and collaboration I saw in action as we work to advance the next wave of blood cancer care.
For a closer look at some of these scientific developments, Anas Younes the latest article provides more detail.”
All from ASH25 featured in Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies